AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35802209
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (BT) active control condition
Trial: 36501158
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg BM of glucose (Glu)
Trial: 36501158
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg BM of fructose (Fru)
Trial: 36501158
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg BM of glucose/fructose (GluFru)
Trial: 36501158
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g sucralose (placebo)
Trial: 35908116
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (16 sessions)
Trial: 35347281
Drug: Topical B‐VEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical B‐VEC treatment
Trial: 32419310
Drug: High bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High bicarbonate dialysate concentration (36 mmol/L)
Trial: 32419310
Drug: Bicarbonate dialysate
RxNorm normalized name: Duosol Bicarbonate Dialysate 2-Chamber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate dialysate concentration of 30 mmol/L (Control)
Trial: 36420538
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of Pregnancy Category (PC) letters in drug labeling
Trial: 36420538
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of Pregnancy Category (PC) letters in drug labeling
Trial: 32469870
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement from pre-conception to term (PC-T)
Trial: 32469870
Drug: Food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food supplement from mid-gestation to term (MG-T)
Trial: 34476629
Drug: M1 a‐tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M1 a‐tDCS concurrent with physical therapy (PT) for 10 sessions of 20 minutes each
Trial: 34476629
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group received sham tDCS concurrent with physical therapy (PT) for 10 sessions of 20 minutes each
Trial: 34476629
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only physical therapy (PT) for 10 sessions of 20 minutes each
Trial: 33958657
Drug: Weekly iron-folic
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron-folic acid supplementation (WIFAS)
Trial: 36070638
Drug: Solriamfetol 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 37.5 mg/day (OSA only), 75 mg/day, 150 mg/day, 300 mg/day
Trial: 36070638
Drug: Solriamfetol (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol (combined doses)
Trial: 35217575
Drug: Single-agent ieramilimab
RxNorm normalized name: Ieramilimab
DrugBank: Ieramilimab (DB16419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent ieramilimab
Trial: 35217575
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ieramilimab and spartalizumab
Trial: 34518266
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment with standard glycaemic control
Trial: 34518266
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment with standard glycaemic control
Trial: 34518266
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment with intensive glycaemic control
Trial: 34518266
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment with intensive glycaemic control
Trial: 34518266
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment for those with cognitive impairment
Trial: 34518266
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment for those with cognitive impairment
Trial: 34518266
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment for those with normal cognitive function
Trial: 34518266
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment for those with normal cognitive function
Trial: 32915300
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 20 mL of 0.375% levobupivacaine
Trial: 32915300
Drug: Retrolaminar block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrolaminar block (RLB) with 20 mL of 0.375% levobupivacaine
Trial: 32140719
Drug: Seabuckthorn oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seabuckthorn oil augmented in 16:1n-7t (480 mg 16:1n-7t/d)
Trial: 32140719
Drug: Unmodified seabuckthorn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmodified seabuckthorn oil (1520 mg 16:1n-7c/d)
Trial: 36239033
Drug: Aripiprazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (2 mg/day, adjusted to 1-10 mg/day)
Trial: 32940187
Drug: Tocilizumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (monoclonal antibody against IL-6 receptors)
Trial: 37815091
Drug: High Protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Protein Diet via Whey Protein Supplementation (PRO, 2 × 25 g whey protein isolate/d)
Trial: 37815091
Drug: Control (CON,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (CON, 2 × 23.75 g maltodextrin/d)
Trial: 33683019
Drug: Peramivir 600
RxNorm normalized name: peramivir 600 mg in 60 mL INTRAVENOUS SOLUTION [Rapivab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peramivir 600 mg repeat-dose
Trial: 33683019
Drug: Peramivir 300
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Peramivir 300 mg single-dose
Trial: 35465686
Drug: MK‐7 (720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐7 (720 µg) plus vitamin D (25 µg)
Trial: 34791634
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide extended-release (TA-ER) 32 mg
Trial: 34849957
Drug: Sofosbuvir/daclatasvir 400/60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir/daclatasvir 400/60 mg once-daily
Trial: 32674048
Drug: 15‐mg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15‐mg oral methotrexate per week
Trial: 32674048
Drug: 3–5‐mg/kg/day cyclosporine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3–5‐mg/kg/day cyclosporine
Trial: 33934389
Drug: Resveratrol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (1000 mg/day)
Trial: 36181304
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day placebo
Trial: 36181304
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day melatonin
Trial: 36181304
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day melatonin plus 30 min of bright light therapy (BLT)
Trial: 35700691
Drug: Bilastine 20
RxNorm normalized name: Bilastine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilastine 20 mg under fasting conditions
Trial: 35700691
Drug: Bilastine 20
RxNorm normalized name: Bilastine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilastine 20 mg under fed conditions
Trial: 33189179
Drug: Progestogen-only pill
RxNorm normalized name: vaginal ring with progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestogen-only pill (75 μg desogestrel) plus a rapid access card to a sexual and reproductive health clinic
Trial: 32975923
Drug: Neurofascial dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofascial dextrose prolotherapy (8 mL of 12.5% dextrose and 40 mg of 2% lidocaine, injected 2 times with 1-week interval)
Trial: 34939872
Drug: Training in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training in coping skills and coping with stress self-efficacy (15 sessions, twice per week for 8 weeks)
Trial: 34939872
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy (control group)
Trial: 32949140
Drug: Seletalisib 45
RxNorm normalized name: Seletalisib
DrugBank: Seletalisib (DB12706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seletalisib 45 mg/day
Trial: 33412997
Drug: Inspiratory Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory Muscle Training (IMT) started from 40% of MIP, given in addition to a neurodevelopmental treatment program for 5 days a week for 6 weeks
Trial: 33412997
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IMT), received the same neurodevelopmental treatment program
Trial: 35729759
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg oral dose)
Trial: 34158376
Drug: Serratus block
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serratus block (ropivacaine 0.5%; 20 mL unilateral; 16 mL/side bilateral)
Trial: 34158376
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral block (ropivacaine 0.5%; 20 mL unilateral; 16 mL/side bilateral)
Trial: 32183769
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behaviour therapy (ICBT) with a comprehensive pre-treatment assessment interview
Trial: 32183769
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behaviour therapy (ICBT) with guidance from a health educator
Trial: 32183769
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behaviour therapy (ICBT) without pre-treatment assessment interview
Trial: 32183769
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behaviour therapy (ICBT) without guidance from a health educator
Trial: 33636418
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of fish oil ω‐3 fatty acids daily
Trial: 33636418
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of fish oil n‐3 fatty acids and 500 mL of reduced‐calorie cranberry juice daily
Trial: 34639600
Drug: FIBROWALK plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIBROWALK plus Treatment-As-Usual (TAU)
Trial: 32323706
Drug: Probiotics administration
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics administration
Trial: 33736696
Drug: Early ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early ART initiation (within 2 weeks after anti-CMV therapy)
Trial: 33736696
Drug: Deferred ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferred ART initiation (more than 2 weeks after anti-CMV therapy)
Trial: 35320643
Drug: Hydrocortisone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (4 mg per kilogram of body weight per day tapered over a period of 10 days)
Trial: 34787240
Drug: Adjuvant low‐laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant low‐laser light therapy
Trial: 34787240
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (topical and compressive treatment)
Trial: 35697890
Drug: Intensified medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified medical therapy
Trial: 33236860
Drug: Incisional negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional negative pressure wound therapy (INPWT) applied after primary closure of the midline sternotomy (n = 52)
Trial: 33236860
Drug: Incisional negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional negative pressure wound therapy (INPWT)
Trial: 33782092
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence management intervention
Trial: 34924513
Drug: Antigravity treadmill
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antigravity treadmill therapy
Trial: 32198963
Drug: TAP catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP catheter group (TAP-C) infused with 0.2% ropivacaine at 10 mL/h
Trial: 32198963
Drug: TAP saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP saline group (TAP-S) infused with saline at 10 mL/h
Trial: 32747302
Drug: Fluoropyrimidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoropyrimidine plus bevacizumab as maintenance treatment
Trial: 32747302
Drug: Fluoropyrimidine alone
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluoropyrimidine alone as maintenance treatment
Trial: 33449848
Drug: Inorganic nitrate
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inorganic nitrate supplementation (4.03 mmol nitrate and 0.29 mmol nitrite daily for 4 weeks)
Trial: 32887850
Drug: Self-efficacy intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-efficacy intervention (six weekly individual physical therapy sessions for lower-extremity exercise and fitness walking; nine biweekly nurse telephone counseling sessions)
Trial: 32887850
Drug: Attention-control intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Attention-control intervention (six weekly and nine biweekly nurse telephone sessions on health topics)
Trial: 34245081
Drug: HepB-alum vaccine
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HepB-alum vaccine
Trial: 34245081
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HepB-alum vaccine)
Trial: 32112114
Drug: remifentanil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil (3 μg/kg) + propofol (2.5 mg/kg)
Trial: 32112114
Drug: sufentanil (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil (0.3 μg/kg) + propofol (2.5 mg/kg)
Trial: 36214061
Drug: 2% minoxidil
RxNorm normalized name: MINOXIDIL 2 g in 100 mL TOPICAL LIQUID [2% Minoxidil hair growth serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% minoxidil combined with microneedling (weekly)
Trial: 36214061
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (microneedling + minoxidil)
Trial: 34482089
Drug: CAC-disclosed group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAC-disclosed group (atorvastatin treatment)
Trial: 33609618
Drug: Structured clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured clinical algorithm for scheduled counselling, glucose monitoring, and adjustment of medication
Trial: 33176772
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health assessment using WHO Oral Health Assessment form 1997 and WHO oral health assessment questionnaire for adult/children 2013
Trial: 33176772
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of treatment needs
Trial: 35131037
Drug: Semaglutide 1·7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 1·7 mg
Trial: 34099328
Drug: IHV01 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IHV01 vaccine (75 µg, 150 µg, and 300 µg doses)
Trial: 34099328
Drug: IHV01 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IHV01 vaccine
Trial: 32419935
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral dexamethasone 0.3 mg/kg (maximum 12 mg)
Trial: 32419935
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone 0.6 mg/kg/day for 2 days (maximum 16 mg/day)
Trial: 32419935
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 1.5 mg/kg/day for 5 days (maximum 60 mg/day)
Trial: 34156758
Drug: Spray-on skin
RxNorm normalized name: benzethonium Topical Spray [New-Skin Liquid Bandage]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray-on skin (ReCell)
Trial: 32737577
Drug: Oral dexamethasone
RxNorm normalized name: dexamethasone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexamethasone (2.5 mg on two successive days a week)
Trial: 32737577
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (up to 2 g for 180 days)
Trial: 35210348
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of intravenous TXA administered intraoperatively
Trial: 35210348
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) administered intraoperatively
Trial: 33490018
Drug: HPHB intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HPHB intervention (a combination of health and parenting intervention augmenting routine ultrasound)
Trial: 33284796
Drug: Normal (0.011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal (0.011 ml supplement/kg bodyweight)
Trial: 33284796
Drug: High (0.063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High (0.063 ml supplement/kg bodyweight)
Trial: 33158717
Drug: Shufeng Jiedu
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shufeng Jiedu capsules (SFJDC) added to standard antiviral therapy (AVD)
Trial: 33158717
Drug: Shufeng Jiedu
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shufeng Jiedu capsules (SFJDC)
Trial: 35189953
Drug: Gabapentin 900
RxNorm normalized name: gabapentin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 900 mg/day for 10 weeks
Trial: 32718816
Drug: RSVΔG vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVΔG vaccine (6.5 log10 CCID50)
Trial: 37591656
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement treatment (HRT)
Trial: 36495282
Drug: pFMI (90-µg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pFMI (90-µg)
Trial: 34455726
Drug: Lettuce seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lettuce seed syrup (5 mL twice daily)
Trial: 34455726
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup (5 mL twice daily)
Trial: 32910478
Drug: Pembrolizumab administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab administered after CRT (arm 1)
Trial: 32910478
Drug: Pembrolizumab administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab administered during CRT (arm 2)
Trial: 34476445
Drug: Improved atraumatic
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved atraumatic restorative treatment (ART) with high-intensity glass ionomer cement
Trial: 34476445
Drug: Conventional cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cavity preparation and composite resin filling (Control)
Trial: 34767321
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G benzathine injections every 4 weeks for 2 years